{"id":56255,"date":"2024-10-25T12:24:39","date_gmt":"2024-10-25T12:24:39","guid":{"rendered":"https:\/?p=56255"},"modified":"2024-10-25T12:24:39","modified_gmt":"2024-10-25T12:24:39","slug":"centene-corp-q3-analysis","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/centene-corp-q3-analysis\/","title":{"rendered":"Centene Corp Reports 22% Membership Growth and $1.2B in Share Repurchases"},"content":{"rendered":"

Centene Corporation (CNC)<\/a> announced its financial results for the third quarter ending on September 30, 2024. The healthcare company reported a solid performance, showing resilience amidst market challenges and delivering on key financial indicators. Let\u2019s dive into the highlights from Centene\u2019s Q3 earnings report, examining the implications for investors.<\/p>\n

Before we dive in, we have a special offer! For a limited time, you can get 70% off Stock Target Advisor\u2019s premium features. Claim your discount<\/a> here!<\/p>\n

\"Promotion<\/a><\/p>\n

Key Insights from Centene Corp\u2019s Earnings Report:<\/h2>\n

Centene\u2019s Q3 report revealed a diluted EPS of $1.36 and an adjusted diluted EPS of $1.62. The company reaffirmed its 2024 adjusted diluted EPS guidance floor of greater than $6.80, signaling confidence in its annual performance. The company\u2019s premium and service revenues reached $36.9 billion, reflecting a 6% increase from the same period last year. Notably, Centene experienced substantial growth in its Marketplace and Medicare Prescription Drug Plan memberships, with increases of 22% and 49% respectively.<\/p>\n

The health benefits ratio (HBR) rose to 89.2% in Q3, up from 87.0% last year, driven by higher acuity in Medicaid members. The company continued its share repurchase activities, buying back $1.2 billion worth of shares during Q3, with an additional $380 million repurchased in October 2024.<\/p>\n

<\/p>\n

\n
\n

CNC Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n